OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HONG59

Hong Seng Consolidated Bhd

Healthcare Facilities & ServicesVerified

The company maintains a strong liquidity position, with a current ratio of 11.82, indicating a high ability to meet short-term obligations. However, its operating cash flow is negative at -44,926,720 MYR, which contrasts with its high current ratio and suggests potential cash flow management challenges. The debt-to-equity ratio is 0.19, reflecting a conservative capital structure with limited leverage. Profitability metrics show a return on equity of 7.68% and a return on assets of 6.24%, both below the typical thresholds for high-growth healthcare firms. The operating income of 25,518,380 MYR is positive, but the gross profit is negative at -27,861,110 MYR, indicating significant cost pressures in production or sourcing. Revenue is concentrated across five segments: Healthcare, Financial Services, Gloves, Search and Advertising, and Others. The Healthcare segment is the most prominent, covering diagnostics, medical research, and pharmaceutical wholesale. The Gloves segment is a core manufacturing business, while Financial Services and Search and Advertising contribute smaller but diversified revenue streams. The company's growth trajectory is mixed. Recent revenue of 168,218,600 MYR includes a reported last actual revenue of 54,109,000 MYR, suggesting volatility in reporting periods or business performance. The capital expenditure of -13,839,730 MYR indicates ongoing investment in operations, but the negative operating cash flow raises questions about the sustainability of such spending. Risk factors include a negative net cash position after subtracting total debt, which could limit financial flexibility. The dilution risk is assessed as low, with no significant dilution potential in the near term. However, the ESG controversies score of 100.0 highlights potential governance and reputational risks that could affect stakeholder confidence. Recent events include a high ESG controversies score and a low governance pillar score of 28.6, indicating potential governance weaknesses. No recent filings or transcripts were provided, but the financial snapshot suggests a need for closer monitoring of cash flow and debt management.

30-day price · HONG-0.01 (-50.0%)
Low$0.01High$0.01Close$0.01As of17 May, 00:00 UTC
Profile
CompanyHong Seng Consolidated Bhd
TickerHONG.KL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Hong Seng Consolidated Bhd operates as an investment holding company with primary business segments in gloves manufacturing and trading, healthcare services, and financial services, generating revenue through diagnostics, health screening, pharmaceutical wholesale, and moneylending.

Classification. The company is classified under the Healthcare economic sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

The company maintains a strong liquidity position, with a current ratio of 11.82, indicating a high ability to meet short-term obligations. However, its operating cash flow is negative at -44,926,720 MYR, which contrasts with its high current ratio and suggests potential cash flow management challenges. The debt-to-equity ratio is 0.19, reflecting a conservative capital structure with limited leverage. Profitability metrics show a return on equity of 7.68% and a return on assets of 6.24%, both below the typical thresholds for high-growth healthcare firms. The operating income of 25,518,380 MYR is positive, but the gross profit is negative at -27,861,110 MYR, indicating significant cost pressures in production or sourcing. Revenue is concentrated across five segments: Healthcare, Financial Services, Gloves, Search and Advertising, and Others. The Healthcare segment is the most prominent, covering diagnostics, medical research, and pharmaceutical wholesale. The Gloves segment is a core manufacturing business, while Financial Services and Search and Advertising contribute smaller but diversified revenue streams. The company's growth trajectory is mixed. Recent revenue of 168,218,600 MYR includes a reported last actual revenue of 54,109,000 MYR, suggesting volatility in reporting periods or business performance. The capital expenditure of -13,839,730 MYR indicates ongoing investment in operations, but the negative operating cash flow raises questions about the sustainability of such spending. Risk factors include a negative net cash position after subtracting total debt, which could limit financial flexibility. The dilution risk is assessed as low, with no significant dilution potential in the near term. However, the ESG controversies score of 100.0 highlights potential governance and reputational risks that could affect stakeholder confidence. Recent events include a high ESG controversies score and a low governance pillar score of 28.6, indicating potential governance weaknesses. No recent filings or transcripts were provided, but the financial snapshot suggests a need for closer monitoring of cash flow and debt management.
Key takeaways
  • The company has a strong current ratio but faces negative operating cash flow, indicating potential liquidity management issues.
  • Return on equity and return on assets are below typical thresholds for a healthcare firm, suggesting room for improvement in profitability.
  • Revenue is spread across multiple segments, with Healthcare being the most significant contributor.
  • The company is investing in capital expenditures but is experiencing negative operating cash flow, which could affect long-term growth.
  • ESG controversies and governance risks are high, which may impact stakeholder trust and regulatory compliance.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$16.8M
Gross profit-$27.9M
Operating income$25.5M
Net income$24.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$44.9M
CapEx-$13.8M
Free cash flow
Total assets$384.3M
Total liabilities$72.4M
Total equity$311.9M
Cash & equivalents
Long-term debt$60.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$311.9M
Net cash-$60.4M
Current ratio11.8
Debt/Equity0.2
ROA6.2%
ROE7.7%
Cash conversion-1.9%
CapEx/Revenue-82.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricHONGActivity
Op margin151.7%11.5% medp25 9.9% · p75 15.0%top quartile
Net margin142.4%8.6% medp25 6.3% · p75 12.4%top quartile
Gross margin-165.6%28.8% medp25 28.8% · p75 28.8%bottom quartile
CapEx / revenue-82.3%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity19.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Observations
IR observations
Last actual revenue54,109,000 MYR
market data ESG controversies score100.0
market data ESG governance pillar28.6
market data ESG social pillar56.2
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 20:53 UTC#e6211aac
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 20:54 UTCJob: 6027d3dd